XORTX Therapeutics XRTX
NASDAQ XRTX
$0.97 +0.04 (+4.30%)
At close: Oct 22, 2026 · 4:00 PM EDT

XORTX Therapeutics (XRTX) Return on Equity [ROE] (2021 - 2026)

Updated

XORTX Therapeutics' Return on Equity [ROE] was 10.54% in the quarter ended Jun 30, 2026, up 152.60 percentage points from -142.06% a year earlier but down 58.25 percentage points from the prior quarter.

Analysis

XORTX Therapeutics (XRTX) Return on Equity [ROE] (2021 - 2026) Analysis & Trends

For the year ended Dec 31, 2025, Return on Equity [ROE] at XORTX Therapeutics came in at -98.00%, down 14.94 percentage points from the prior year.

  • Return on Equity [ROE] shows a five-year change of -408.63 percentage points (years ended Dec 2020 to Dec 2025).
  • In earlier years, Return on Equity [ROE] was -83.06% in the year ended Dec 31, 2024 (-45.97 pp), -37.08% in the year ended Dec 31, 2023 (+39.34 pp), -76.43% in the year ended Dec 31, 2022 (-57.84 pp) and -18.58% in the year ended Dec 31, 2021 (-329.22 pp).
  • Quarterly Return on Equity [ROE] has moved between -142.06% (the quarter ended Jun 30, 2025) and 68.79% (the quarter ended Mar 31, 2026) over five years.
  • Compared with a year earlier, Return on Equity [ROE] has increased for three straight quarters, with an average year-over-year change of +32.74 percentage points over the last eight quarters.
  • The best year-over-year quarter for Return on Equity [ROE] over five years was the quarter ended Jun 30, 2026 (a gain of 152.60 percentage points); the worst was the quarter ended Dec 31, 2022 (a drop of 102.07 percentage points).
  • Per Business Quant data, XRTX's Return on Equity [ROE] in the three quarters before the quarter ended Jun 30, 2026 was 68.79% (quarter ended Mar 31, 2026), -30.23% (quarter ended Dec 31, 2025) and -93.16% (quarter ended Sep 30, 2025).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROE (Qtr)
1 Eli Lilly 1,144.36 Bn 1,112.95 Bn 19.71 Bn 82.09%
2 Johnson & Johnson 635.36 Bn 555.22 Bn 17.30 Bn 19.33%
3 AbbVie 502.79 Bn 475.90 Bn 12.70 Bn -
4 Merck 356.08 Bn 310.46 Bn 12.21 Bn 7.21%
5 Novartis Ag 300.87 Bn 264.86 Bn 11.24 Bn 31.52%
6 Astrazeneca 264.31 Bn 237.99 Bn 12.86 Bn 21.39%
7 Amgen 239.07 Bn 194.47 Bn 7.24 Bn 83.75%
8 Gilead Sciences 194.50 Bn 168.70 Bn 6.22 Bn -18.38%
9 Pfizer 171.00 Bn 117.64 Bn 10.94 Bn 4.97%
10 XORTX Therapeutics 871,267.51 -2.43 Mn - 10.54%
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 10.54%
Mar 31, 2026 68.79%
Dec 31, 2025 -30.23%
Sep 30, 2025 -93.16%
Jun 30, 2025 -142.06%
Mar 31, 2025 -131.40%
Dec 31, 2024 -150.58%
Sep 30, 2024 -59.43%
Dec 31, 2023 -52.91%
Sep 30, 2023 -110.30%
Jun 30, 2023 -88.72%
Mar 31, 2023 -103.00%
Dec 31, 2022 -133.03%
Sep 30, 2022 -0.70%
Jun 30, 2022 -54.35%
Mar 31, 2022 -25.67%
Jun 30, 2021 -26.38%
API Access

XORTX Therapeutics Return on Equity [ROE] API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=return-on-equity-%5Broe%5D&ticker=XRTX&period=max&api_key=YOUR_API_KEY